New PET scan tracks immune response in melanoma patients

NCT ID NCT05279027

Ongoing Knowledge-focused Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This early-phase trial tested a special PET/CT imaging agent, Zirconium Zr 89 Crefmirlimab Berdoxam, to see if it can measure immune activity in tumors of patients with advanced melanoma. Six adults on immunotherapy plus hydroxychloroquine received scans before and after starting treatment. The goal was to see if changes in the scan could predict how well the cancer responds to therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Zirconium Zr 89 Crefmirlimab Berdoxam
What this could lead to: If successful, this imaging method could help doctors see early on whether immunotherapy is working in melanoma patients, potentially guiding treatment decisions.
What could go wrong: This is a very small, early-phase study with only 6 participants, so results may not apply to all patients. The imaging agent is experimental and may not reliably predict treatment response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA (SKIN)

Contacts and locations

Locations

Perleman Center for Advanced Medicine

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.